Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | GFER | P55789 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | HTR7 | P34969 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27540392 | 0.85 | PTGS2 (0.67) | PTGS2PTGS1GFERCYP1A2CYP3A4 | |
| SCHEMBL5672007 | 0.84 | PTGS2 (0.81) | PTGS2PTGS1GFERCA1CA2 | |
| SCHEMBL5670285 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1GFERCA1CA2 | |
| SCHEMBL19306221 | 0.82 | HTR7 (0.80) | PTGS2PTGS1HTR7 | |
| SCHEMBL5670856 | 0.80 | PTGS2 (0.79) | PTGS2PTGS1GFERCA1CA2 | |
| SCHEMBL5671915 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1GFERCA1CA2 | |
| SCHEMBL5672162 | 0.77 | PTGS2 (0.74) | PTGS2PTGS1GFERCA1CA2 | |
| SCHEMBL19306049 | 0.73 | HTR7 (0.75) | HTR7 | |
| SCHEMBL28627439 | 0.73 | PTGS2 (0.58) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL19306453 | 0.72 | HTR7 (0.63) | PTGS2GFERCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506180-A4 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORP (KR) | 2006-04-05 | — | — | EP | claimed |
| EP-1506180-A1 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ Corporation (KR) | 2005-02-16 | — | — | EP | claimed |
| US-6777434-B2 | CYCLOOXYGENASE INHIBITOR, ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | CJ CORP. (KR) | 2004-08-17 | — | — | US | claimed |
| WO-2003097620-A1 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORPORATION (KR) | 2003-11-27 | — | — | WO | claimed |
| US-20030216454-A1 | Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2003-11-20 | — | — | US | claimed |
| EP-1506180-A4 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORP (KR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1506180-A1 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ Corporation (KR) | 2005-02-16 | — | — | EP | disclosed |
| US-6777434-B2 | CYCLOOXYGENASE INHIBITOR, ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | CJ CORP. (KR) | 2004-08-17 | — | — | US | disclosed |
| WO-2003097620-A1 | THIAZOLIDINE-4-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORPORATION (KR) | 2003-11-27 | — | — | WO | disclosed |
| US-20030216454-A1 | Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216454-A1 | Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same | SLC5A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1 | PTGS2 3143/4885PTGS1 1150/4885GFER 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.